Event:	Central Nervous System Disease Conference
Date/Time:	Thursday, November 17, 2016
Location:	Maxim Group LLC, New York, NY

Related Posts

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease
July 29, 2021

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
June 28, 2021

Anavex Life Sciences Announces Closing of $50 Million Registered Direct Offering
June 24, 2021

Anavex Life Sciences Announces $50 Million Registered Direct Offering
June 22, 2021